entertainment -WSS

entertainment

author：Wikipedia 2025-09-29 01:09:34 - browse：543

Among the pharmaceutical companies’ many objections to the Biden administration’s drug pricing program is a set of provisions the industry says will warp how cancer drugs are developed. On Wednesday, AstraZeneca CEO Pascal Soriot proposed a new solution.

“What we were asking — and are asking now — is a very simple fix,” said Soriot at the STAT Future Summit, saying that “the impact on health care costs would be very marginal.”

The problem, executives say, is that companies developing cancer drugs today generally start small and then go big. They seek approval first in a small setting, such as patients who have exhausted all other therapies, where it’s easiest in terms of trial size and length to show a benefit. Then they go into larger settings, such as newly diagnosed patients, where studies take longer but the revenue potential is much higher.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Virginia high school admissions case could be legal follow
Next article： Death of patient in Alzheimer’s trial raises question of possible risks

focus

WSS

Primary care doctor shortage won't be solved by free med school tuition

Brain technologies pose threats that are all too real, experts warn

Why we need to separate burnout from moral injury in health care

PBM executives asked to testify by House panel

Study: Lilly Alzheimer's therapy slowed patients' cognitive decline

Why we need to separate burnout from moral injury in health care

focus

entertainment

focus

BioMarin wins approval for gene therapy to treat hemophilia A

Brain MRIs reveal impact of 'toxic stress' on Black children

As demand for Covid shots wanes, Moderna seeks its next success

Black vets could get higher VA benefits if race not used in lung test

As demand for Covid shots wanes, Moderna seeks its next success

Warren pushes Witty on UnitedHealth's control over physicians

United colonoscopy coverage change 'may cost lives,' doctors say

Weight bias in eating disorder treatment complicated by new weight loss drugs

Sports medicine is finally prioritizing gender equality

New guidelines on severe brain injury complicate already difficult decisions

knowledge

Paxlovid study fails to answer questions over benefit for broader groups

Death of patient in Alzheimer’s trial raises question of possible risks

What is the Wagner Group? The 'brutal' Russian military unit in Ukraine

Novel spinal cord stimulator treats paralysis without surgery

Lawmakers grill UnitedHealth CEO on Change cyberattack

Why drug prescriptions should include diagnoses

focus

knowledge

focus

leisure time